drugset / Trial / NCT03287791

A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea

NCT03287791

Phase 3 Completed 924 enrolled Actavis Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objectives of this study were to compare the safety and efficacy profiles of a generic Azelaic Acid Foam, 15% to the reference listed Finacea® (azelaic acid) Foam, 15% and to demonstrate therapeutic equivalence and safety of the two active foams in the treatment of moderate facial rosacea, and to demonstrate superiority of the Reference and Test products over the Vehicle.

Timeline

Start
2016-07-19
Primary completion
2017-06-22
Completion
2017-06-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Azelaic acid Small molecule 15 % Topical

Indications